The novel field of regenerative medicine has recently expanded with the use of stem cells as effective therapeutic tools for ortho pedic surgery 1, 2) . Inherent selfrenewal properties of stem cells and their differentiation potential into the multiple lineages hold promise to overcome the limitations of current therapeutic op tions. An ideal stem cell source should be easily accessible by a minimally invasive procedure; the procedure should be costef fective for clinical translation, and the isolated cells should safely encompass autologous and/or allogeneic therapies; moreover, the stem cells should have high proliferative capacity with a high po tential for differentiation into multiple lineages in a controllable and reproducible manner.
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Adipose Tissue as a Source of Stem Cells
Mesenchymal stem cells (MSCs) were originally identified with in bone marrow and their multipotency generates a great deal of interest 3) . However, the low amount of MSCs harvested from the bone marrow (bone marrowderived mesenchymal stem cells [BMSCs] ) through an invasive aspiration procedure created the need for further ex vivo expansion. In this sense, multipotent stem cells derived from adipose tissue with similar characteristics to BMSCs, called adiposederived stem cells (ASCs), were found to be a more feasible and promising candidate for stem cell pool 4) . This promise emanated from such properties of ASCs including their abundance in human body, their ease of accessibility and simpler isolation procedure as compared to aspiration from bone marrow, resulting in less patient discomfort and less risk associ ated with the surgical procedure 5, 6) . Moreover, ASCs have the capacity to proliferate to a higher degree as compared to BMSCs with a greater rate of stem cell marker expression 7, 8) . Furthermore, it has been shown that ASCs are more resistant to apoptosis than BMSCs in in vitro conditions 9) . ASCs 11, 12) . For example, the immunomodulatory capacities of BMSCs and ASCs obtained by one step cell concentration (stromal vascular fraction [SVF] ) from agematched donors were compared and it was shown that cells from SVF have more po tent immunomodulatory effects which is related with higher lev els of cytokine secretion 13) . In another study, ASCs were shown to display a higher rate of B cell inhibition compared to BMSCs 11) . Even though MSCs derived from either source were capable of inhibiting NK and T cell activation, ASCs indicated a higher overall inhibitory effect 14) . Overall, ASCs are characterized by im munosuppressive properties and low immunogenicity 6) .
Infrapatellar Fat Pad-Derived Stem Cells
ASCs used in cell therapy are obtained mostly from subcuta neous adipose tissue by liposuction (SCASCs). On the other hand, the potential of ASCs isolated from infrapatellar fat pad (IPFPASCs), which is located in close proximity to the synovial membrane, in knee joint cartilage repair has fueled great interest in their therapeutic potential. The main promise of IPFPASCs over other MSC sources is that these cells show ageindependent proliferation and differentiation potential, whereas others gener ally possess agerelated decrease in these properties 15) . Moreover, IPFPASC's significant chondrogenic potential makes them promising candidates for exploration of use in other tissue regen erative approaches 16) .
Isolation and Characterization
IPFP is routinely removed as surgical waste during knee ar throplasty, and it represents an accessible source of ASCs. In 1904, Hoffa described the surgical removal of IPFP, and after that Kumar mentioned an arthroscopic technique to ablate IPFP in 2007 17) . In brief, for the isolation of the IPFP during knee arthro plasty in our clinical setting, the tourniquet was inflated and then limited medial parapatellar skin incision (ca. 10 cm in length) was performed beginning 2 cm proximal to the superior pole of the patella and passing along the medial border of the patella to the medial border of the tibial tubercle. Afterwards, the IPFP was exposed and excised. This excised IPFP can be directly minced and the emerging stromal fraction including the stem cells can be directly used in the regeneration of bone, cartilage or soft tissues within the knee during surgery. For the isolation of ASCs from the excised IPFP, the tissue was transferred to the laboratory and the following procedure was applied under sterile conditions. IPFP was washed with sterile phosphatebuffered saline (PBS) to remove the blood and then was mechanically chopped into small pieces. The tissue was then digested enzymatically (0.1% collagenase type I, 1% bovine serum albumin and 2 mM CaCl 2 within sterile PBS) for 1 hour at 37°C under constant agitation within 50 mL tubes. Tubes were then centrifuged and the pellet was resuspended in PBS. Cell suspension was passed through a cell strainer and cells were collected in fresh tubes. After a second centrifugation step to remove the remaining fatty constituents, cell pellet was suspended in cell culture media including high glucose Dulbecco's Modified Eagle Medium (DMEM) supple mented with 10% fetal bovine serum, 1% antibiotics and 1 ng/mL FGF2, cultured normally and stored within liquid nitrogen.
The independence of agerelated decrease in stemness makes IPFPASCs a very promising cell source for stem cellbased therapy. In routine cellular therapy approaches, the age of the patient is a crucial parameter that sometimes limits the success of the therapy. For example, human BMSCs isolated from donors of higher age have been shown to be lesser in amount with a reduced lifespan and diminished capacity of proliferation and os teogenic differentiation 18) . In another study where the osteogenic differentiation potential of ASCs and BMSCs were compared between young (mean±standard deviation [SD], 36.4±11.8 years) and elderly (mean±SD, 71.4±3.6 years) patients, it was observed that the level of matrix mineralization of ASCs was comparable between young and aged patients, whereas BMSCs from aged pa tients produced less amount of mineral deposits and had a lower expression level of osteogenic genes as compared to the cells from the young patients 19) . Although there is no direct comparison of BMSCs to IPFPASCs in terms of proliferative and differentiation capacity with aging, the study of Khan et al. 15) compared IPFP ASCs isolated from patients of different age groups in terms of their proliferative capacity as well as their potential of epitopes and osteogenesis. It was shown in this study that there was no significant difference in proliferation rate at any defined time between cells from different groups. Considering cell surface epitopes, mesenchymal markers including CD13, CD44, CD90, CD105 and CD29 have shown positive staining for all age groups. On the other hand, little or no staining was observed for the fol lowing markers: 3G5 for vascular pericytes, LNGFR and STRO1 for BMSCs and CD34 for hematopoietic stem cells. These sug gested a homogenous population and the lack of hematopoietic cells during isolation. Negative staining for CD56 (neural cell adhesion molecule marker for neurogenic and myogenic cells) has also revealed the isolation of a pure population without con tamination of the cells of the tissues mentioned. As a result, IPFP ASCs have shown similar characteristics of MSCs in terms of sur face marker expression and these characteristics were maintained with ageing. In another study, the characteristics and differentiation abili ties of IPFPASCs and SCASCs were examined 20) . It was found that IPFPASCs and SCASCs had similar cell surface profiles demonstrated by flow cytometry including positive expression of CD73, CD90 and CD105 and negative expression of CD34 and CD45. With respect to differentiation ability, IPFPASCs showed superiority in osteogenic and chondrogenic differentiation over SCASCs as assessed by SOX9 (chondrogenic transcription fac tor) and RUNX2 (transcription factor expressed in MSCs upon their commitment toward osteogenic differentiation). It was con cluded that the anatomical area where cells are isolated affects the characteristics of ASCs, and the level of chondrogenic differentia tion potential of IPFPASCs is higher due to close contact point of IPFP with synovial membrane and fluid 21) . Therefore, IPFP can be considered as a high quality source for stem cellbased re generative therapies.
Biological Mechanisms for Regulation of Cell Behavior
IPFPASCs have shown great potential as a cell source in carti lage tissue engineering, where they were shown to fulfill the cri teria of chondrogenic potential at a comparable level to MSCs 16) . Chondrogenic differentiation of ASCs from various sources is usually induced by culturing in differentiation medium contain ing growth factors such as transforming growth factorβ (TGFβ) with its isoforms named as TGFβ1, TGFβ2 and TGFβ3 22) . Dif ferent procedures have been published so far in the literature in terms of types and effective concentrations of TGFβ subtypes. Although there is no report in the literature comparing the effect of three different isoforms of TGFβs on chondrogenic differ entiation for IPFPASCs, Ye et al. 23) showed that culture media consisting of TGFβ3 and bone morphogenic protein6 (BMP6) have strongly enhanced the capacity of chondrogenic differentia tion of IPFPASCs via secretion of collagen type II. Furthermore, the expression of collagen type II and aggrecan located at the extra cellular matrix was confirmed by immunohistochemistry and indicated the hyaline cartilage formation. Hennig et al. 24) described the reason behind the synergistic effect of BMP6 and TGFβ and concluded the contribution of BMP6 was to induce the expression of TGFβ which is not usually expressed by ASCs.
IPFP-ASCs in Tissue Repair and Regeneration
The potential of using IPFPASCs provides a great promise for the field of orthopedics including cartilage and bone repair. IPFP is a nonnegligible source of stem cells for cartilage regen eration due to availability and accessibility of high amount of chondroprogenitor cells within the tissue. Although culturing cells in a threedimensional (3D) environment is the most com mon approach for cartilage tissue engineering 25) , this constitutes a significant barrier for the availability of a suitable piece of tissue analogue for transplantation. In order to overcome this problem and to reduce the time and cost related with the in vitro culturing, Ahearne et al. 26) developed an approach including direct implan tation of TGFβ1 delivery system to cartilage defect site for in situ chondrogenesis of IPFPASCs encapsulated in fibrin hydrogels.
IPFPASCs have also been tested in the remediation of articular cartilage defects resulting from osteoarthritis (OA). In the study of Toghraie et al. 27) , IPFPASCs were injected in rabbit knees and the lesion site was reduced for IPFPASC treated group, while progression of degenerative OA was observed in the nontreated group. In another study, Buckley et al. 16 ) encapsulated IPFP ASCs into agarose hydrogel exposed to TGFβ3 and applied load to the gel in order to mimic the natural microenvironment of the tissue. As another strategy to produce 3D tissue, IPFPASCs combined with TGFβ3 and BMP6 were 3D printed within a chitosan scaffold having a pore size of 250 μm 23) . It was observed by gene expressions based on collagen type II and SOX9 at the end of 4th week of in vitro culture that the gene expressions were significantly upregulated, indicating cartilage formation. IPFP ASCs were also used for the generation of a selfassembled carti lage construct on poly (εcaprolactone) films 28) . It was shown that tissues formed on these films were rich in sulfated glycosamino glycan and collagen type II. In addition to the cartilage degenera tion, Dragoo et al. 29) demonstrated the applicability of IPFPASCs encapsulated fibrin masses to repair articular surfaces as well as to provide increased bone regeneration. The studies mentioned above and some other studies available in the literature that used IPFPASCs for regenerative applica tions in orthopedics are listed in Table 1 .
Clinical Applications of ASCs in Orthopedics
In clinical perspective, patients have benefited from advances Fibrin micromass Cartilage and bone IPFPASCs were seeded into fibrin glue nodule and were cultured using chondrogenic media. . Therefore, IPFPASCs constitute a promising cell source for regenerative therapies of the musculoskeletal tissues in the clinic, regarding their promising preclinical outcomes.
Of the very few examples of clinical use of IPFPASCs, the cells were injected percutaneously to determine the potential improve ment of articular cartilage with a followup period of 1 year 31) . During that period, Lysholm knee scoring, Tegner activity and visual analogue scale (VAS) score were analyzed. After the op eration, almost all patients (92%) showed an improved Lysholm score together with increased VAS score and decreased Tegner activity when compared with preoperated cases. The results of this study imply encouraging effect of IPFPASCs in terms of reducing pain and improving knee function for patients suffering from OA.
Studies involving the use of SCASCs in clinical applications include the study of Dufrane et al. 32) where human SCASCs were used with demineralized bone matrix to form a 3D "bone like" osteogenic structure and transplanted to 6 patients having large bone defects. The ideal size of bone defect was modelled and the 3D graft was put directly into the nonunion part of the bone without any fixation material. In 3 months, the 3D graft promoted bone consolidation and restored the bone anatomy and function without any wound healing, inflammatory reaction or oncological effect. Pak 33) injected SCASCs with hyaluronic acid, platelet rich plas ma and CaCl2 in patients having knee OA. Magnetic resonance imaging (MRI) evidence showed regeneration of the cartilage and bone at 3 months. In another study, Jo et al. 34) described the safety the subchondral bone. As a result, this study not only optimized the cell dose needed for OA therapy by achieving efficacy and safety but also showed the promising results for cartilage regen eration in clinical perspective.
The Promise of IPFP-ASCs in Tissue Engineering Strategies Targeted towards Alternative Musculoskeletal Tissues
IPFPASCs have shown potential as a stem cell source due to their favorable features as easier accessibility, rapid cell doubling times and antiapoptotic potential, as mentioned in the above preclinical regenerative strategies mostly towards cartilage. These promising results have fueled the interest to investigate their po tential in other target tissues. It has been observed that SCASCs have potential as a source of stem cells to develop regenerative strategies for skeletal muscle upon biochemical and mechani cal stimulation 35) . Based on this, the potential of IPFPASCs for the same target application was investigated. IPFPASCs were isolated from IPFP, which was the surgical waste during knee ar throplasty. The myogenic differentiation potential of IPFPASCs were investigated for the first time in the literature. Use of IPFP ASCs to treat skeletal muscle defects may not become a routine clinical application due to the necessity to damage the joint for cell isolation; however, exploration of the underlying molecular mechanisms would help design better therapeutic approaches towards skeletal muscle regenerative therapies.
Isolated primary IPFPASCs were encapsulated within fibrin microfibers produced by wet spinning (Fig. 1A) in order to assess their suitability for use in skeletal muscle tissue engineering. It has been observed that IPFPASCs maintain their viability, pro liferate and elongate through the axis of the fibers during 14 days of in vitro culture (Fig. 1B) . The effect of fiber orientation on the expression of myogenic marker desmin was assessed through im munofluorescence staining performed on cryosections obtained from the cellladen fibers, counterstained for the cell nuclei with draq5 (Fig. 1C) . It was observed that IPFPASCs have produced the muscle specific cytoskeletal protein desmin upon biochemi cal induction.
Conclusion and Future Directions
Stem cells have shown great potential in regenerative medicine over the last decades. In the field of orthopedics, cell therapy ap proaches involving the direct injection of stem cells to the target site have been used. However, growing evidence in the literature supports the use of stem cells together with carrier materials of proper biomimetic structure and characteristics in obtaining bet ter regenerative outcomes. Identification of a proper cell source as well as a proper carrier material for these cells are in the heart of successful stem cellbased regenerative strategies. This proper cell source should be accessible, abundant and should maintain proliferative capacity with higher yields of differentiation. Stem cells isolated from adipose tissue (mostly from the abdominal lipoaspirates) are being investigated increasingly as a potent cell source with the mentioned characteristics. ASCs isolated from the IPFP, on the other hand, have shown even better potential than their abdominal counterparts as they possess higher yields in isolation with enhanced proliferation and differentiation ca pacity. More detailed investigations for the signaling pathways as well as the development of optimized delivery strategies would eventually maximize the efficiency of IPFPASCs in their future clinical use in the orthopedic field.
